MA40605B1 - Composé pyrazolothiazole et médicament - Google Patents
Composé pyrazolothiazole et médicamentInfo
- Publication number
- MA40605B1 MA40605B1 MA40605A MA40605A MA40605B1 MA 40605 B1 MA40605 B1 MA 40605B1 MA 40605 A MA40605 A MA 40605A MA 40605 A MA40605 A MA 40605A MA 40605 B1 MA40605 B1 MA 40605B1
- Authority
- MA
- Morocco
- Prior art keywords
- present
- compound
- pyrazolothiazole
- jak1
- drug
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- VHHWHDFVZGPKRT-UHFFFAOYSA-N 5h-pyrazolo[3,4-d][1,3]thiazole Chemical compound N1=NC2=NCSC2=C1 VHHWHDFVZGPKRT-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 101150079478 jak1 gene Proteins 0.000 abstract 3
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'objectif de la présente invention est de fournir un composé ayant un effet inhibiteur exceptionnel de jak1. Des exemples de la présente invention comprennent des composés pyrazolothiazole représentés par la formule générale [i], ainsi que des sels pharmaceutiquement acceptables de ceux-ci. Les composés de la présente invention ont une activité inhibitrice de jak1. étant donné cette activité inhibitrice jak1, les composés de la présente invention ont également un effet immunosuppresseur (contre, par exem
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014177969 | 2014-09-02 | ||
| PCT/JP2015/074935 WO2016035814A1 (fr) | 2014-09-02 | 2015-09-02 | Composé pyrazolothiazole et médicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40605A MA40605A (fr) | 2017-07-12 |
| MA40605B1 true MA40605B1 (fr) | 2020-10-28 |
Family
ID=55439874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40605A MA40605B1 (fr) | 2014-09-02 | 2015-09-02 | Composé pyrazolothiazole et médicament |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9937176B2 (fr) |
| EP (1) | EP3190116B1 (fr) |
| JP (1) | JP6558372B2 (fr) |
| KR (1) | KR102294330B1 (fr) |
| CN (1) | CN107108653B (fr) |
| AU (1) | AU2015312886B2 (fr) |
| BR (1) | BR112017003800B1 (fr) |
| CA (1) | CA2959721C (fr) |
| CL (1) | CL2017000478A1 (fr) |
| CO (1) | CO2017002982A2 (fr) |
| CY (1) | CY1123320T1 (fr) |
| DK (1) | DK3190116T3 (fr) |
| ES (1) | ES2827243T3 (fr) |
| HR (1) | HRP20201382T1 (fr) |
| HU (1) | HUE050565T2 (fr) |
| IL (1) | IL250729B (fr) |
| LT (1) | LT3190116T (fr) |
| MA (1) | MA40605B1 (fr) |
| MX (1) | MX377926B (fr) |
| MY (1) | MY181814A (fr) |
| NZ (1) | NZ729494A (fr) |
| PE (1) | PE20170668A1 (fr) |
| PH (1) | PH12017500383B1 (fr) |
| PL (1) | PL3190116T3 (fr) |
| PT (1) | PT3190116T (fr) |
| RS (1) | RS60798B1 (fr) |
| RU (1) | RU2688660C2 (fr) |
| SG (2) | SG10201901676UA (fr) |
| SI (1) | SI3190116T1 (fr) |
| SM (1) | SMT202000503T1 (fr) |
| TW (1) | TWI679205B (fr) |
| UA (1) | UA121869C2 (fr) |
| WO (1) | WO2016035814A1 (fr) |
| ZA (1) | ZA201701492B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| US11167953B2 (en) | 2017-06-09 | 2021-11-09 | Mitsubishi Electric Corporation | Passenger conveyor |
| EP4081199A4 (fr) * | 2019-12-23 | 2024-01-17 | SRI International | Inhibiteurs de lipoxygénase |
| WO2025216268A1 (fr) * | 2024-04-09 | 2025-10-16 | 国立研究開発法人国立循環器病研究センター | Agent prophylactique ou thérapeutique contre l'hypertension pulmonaire sévère ou une maladie du tissu conjonctif |
| JP7742516B1 (ja) * | 2025-07-31 | 2025-09-19 | 日本新薬株式会社 | 好酸球性多発血管炎性肉芽腫症の処置剤 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600390A1 (de) | 1986-01-09 | 1987-07-16 | Hoechst Ag | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
| US5017212A (en) * | 1986-03-20 | 1991-05-21 | Takeda Chemical Industries, Ltd. | Sulfonylurea compounds and herbicidal use |
| US5082847A (en) | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
| GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| NZ546058A (en) | 2004-01-12 | 2010-09-30 | Ym Biosciences Australia Pty | Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors |
| CA2563963A1 (fr) | 2004-04-28 | 2005-11-10 | Pfizer Inc. | Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur |
| ZA200802685B (en) * | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| CN103626742B (zh) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| CN102532133A (zh) | 2006-01-17 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| RS52561B (sr) * | 2008-04-15 | 2013-04-30 | Eisai R&D Management Co., Ltd. | Jedinjenje 3-fenilpirazolo[5,1-b]tiazol |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| US8524707B2 (en) * | 2008-12-19 | 2013-09-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| ES2461967T3 (es) | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
| TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
| EP2338888A1 (fr) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK |
| JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| EP2523957A1 (fr) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Composés hétérocycliques tricycliques, leurs compositions et procédés d'utilisation |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| WO2012022045A1 (fr) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Composés pyrrolopyrimidiniques et leurs utilisations |
| WO2012037132A1 (fr) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Dérivés de la phtalazine comme inhibiteurs de jak1 |
| EP2629777B1 (fr) | 2010-10-22 | 2018-12-19 | Merck Sharp & Dohme Corp. | Diamines bicycliques utiles en tant qu'inhibiteurs des kinases janus |
| WO2012085176A1 (fr) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Composés pyrazinones tricycliques, leurs compositions et leurs procédés d'utilisation en tant qu'inhibiteurs de janus kinase |
| WO2013025628A1 (fr) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Composés et procédés d'inhibition de janus kinase |
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
-
2015
- 2015-09-01 TW TW104128865A patent/TWI679205B/zh active
- 2015-09-02 MX MX2017002488A patent/MX377926B/es unknown
- 2015-09-02 ES ES15838466T patent/ES2827243T3/es active Active
- 2015-09-02 US US15/505,767 patent/US9937176B2/en active Active
- 2015-09-02 WO PCT/JP2015/074935 patent/WO2016035814A1/fr not_active Ceased
- 2015-09-02 RS RS20201081A patent/RS60798B1/sr unknown
- 2015-09-02 CA CA2959721A patent/CA2959721C/fr active Active
- 2015-09-02 PL PL15838466T patent/PL3190116T3/pl unknown
- 2015-09-02 HR HRP20201382TT patent/HRP20201382T1/hr unknown
- 2015-09-02 RU RU2017110535A patent/RU2688660C2/ru active
- 2015-09-02 SG SG10201901676UA patent/SG10201901676UA/en unknown
- 2015-09-02 KR KR1020177008967A patent/KR102294330B1/ko active Active
- 2015-09-02 MA MA40605A patent/MA40605B1/fr unknown
- 2015-09-02 SG SG11201701447UA patent/SG11201701447UA/en unknown
- 2015-09-02 CN CN201580058944.7A patent/CN107108653B/zh active Active
- 2015-09-02 HU HUE15838466A patent/HUE050565T2/hu unknown
- 2015-09-02 LT LTEP15838466.9T patent/LT3190116T/lt unknown
- 2015-09-02 SM SM20200503T patent/SMT202000503T1/it unknown
- 2015-09-02 SI SI201531340T patent/SI3190116T1/sl unknown
- 2015-09-02 DK DK15838466.9T patent/DK3190116T3/da active
- 2015-09-02 EP EP15838466.9A patent/EP3190116B1/fr active Active
- 2015-09-02 MY MYPI2017700677A patent/MY181814A/en unknown
- 2015-09-02 JP JP2016546669A patent/JP6558372B2/ja active Active
- 2015-09-02 PE PE2017000370A patent/PE20170668A1/es unknown
- 2015-09-02 BR BR112017003800-5A patent/BR112017003800B1/pt active IP Right Grant
- 2015-09-02 UA UAA201702990A patent/UA121869C2/uk unknown
- 2015-09-02 PT PT158384669T patent/PT3190116T/pt unknown
- 2015-09-02 AU AU2015312886A patent/AU2015312886B2/en active Active
- 2015-09-02 NZ NZ729494A patent/NZ729494A/en unknown
-
2017
- 2017-02-23 IL IL250729A patent/IL250729B/en active IP Right Grant
- 2017-02-28 ZA ZA2017/01492A patent/ZA201701492B/en unknown
- 2017-02-28 CL CL2017000478A patent/CL2017000478A1/es unknown
- 2017-03-01 PH PH12017500383A patent/PH12017500383B1/en unknown
- 2017-03-27 CO CONC2017/0002982A patent/CO2017002982A2/es unknown
- 2017-12-04 US US15/830,181 patent/US9999622B2/en active Active
-
2020
- 2020-09-04 CY CY20201100832T patent/CY1123320T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40605B1 (fr) | Composé pyrazolothiazole et médicament | |
| PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| MA46337A (fr) | Composé de pyridine | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MA33330B1 (fr) | Quinazolines substituées comme fongicides | |
| EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
| TN2020000082A1 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| TN2020000125A1 (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| MA34385B1 (fr) | Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes) | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MY196572A (en) | Amino-Methyl Piperidine Derivative as Kinase Inhibitor | |
| MA38583A1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
| SA519401827B1 (ar) | [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه | |
| MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| BRPI0511433A (pt) | derivados de quinolina substituìda como inibidores de cinesina mitótica | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| MA39983B1 (fr) | Dérivés de carboxamide | |
| MA30664B1 (fr) | Derive d'aminoalcool et immunodepresseur le contenant en tant que principe actif. | |
| WO2020251871A3 (fr) | Nouveaux composés de tétrahydroquinoléine substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) | |
| EA201591369A1 (ru) | Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10) |